Department of Pharmacy & Pharmacology, Unit Catalogue 2010/11 |
PA50233: Infections |
 Credits:
| 6 |
| Level:
| Masters |
| Period: | This unit is available in... |
| Modular (no specific semester) |
| Assessment:
| CW 100% |
| Supplementary Assessment: | Like-for-like reassessment (where allowed by programme regulations) |
| Requisites:
| |
| Description:
| Aims: This clinical module aims to update pharmacists on infectious diseases and patient monitoring factors that should be considered when providing pharmaceutical care for these patients. Learning Outcomes: By the end of the unit the student will be able to: 1. Describe and analyse the role of the healthcare professional/ pharmacist in prescribing and monitoring medication for patients with infectious diseases (knowledge and understanding). 2. Explain the disease and patient monitoring factors that are influenced in this therapeutic area (knowledge and understanding, professional practical skill). 3. Critically evaluate the evidence base and medicines management issues for treatment of infectious diseases and be able to present this information to your peer group (intellectual skill). 4. Reflect on their own practice in prescribing and medicines management issues for these patients and identify areas for continuous improvement (personal transferable skill). 5. To produce an economic evaluation on antibiotic prescribing. Skills: * Planning & organisation (Taught/Facilitated) * Handling information (Taught) * Written communication (Taught/Facilitated/Assessed) * Working with others (Taught) * Improving learning & performance (Taught/Facilitated/Assessed) * Information & communication technology (ICT) (Taught/Facilitated) * Problem solving (Taught/Facilitated/Assessed). Content: * Unit Introduction * Micro-organisms and anti-microbials * Infectious disease management strategies * Community-acquired infections * Lower respiratory tract infections * Gastrointestinal and abdominal infections * Skin, soft tissue, joint and bone infections * CNS infections, endocarditis and septicaemia * Human immunodeficiency virus * Economic evaluation. |